drug · small molecule
vonoprazan fumarate
Marketedupdated 3mo agoby $PHAT Phathom Pharmaceuticals, Inc.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval36 co-mentions · 15 sources
- drugVOQUEZNA24 co-mentions · 15 sources
- tagSmall Molecule18 co-mentions · 15 sources
- drugVOQUEZNA DUAL PAK18 co-mentions · 12 sources
- drugVOQUEZNA TRIPLE PAK18 co-mentions · 12 sources
- drugLarotid12 co-mentions · 12 sources
- drugAMOXICILLIN AND CLAVULANATE POTASSIUM12 co-mentions · 12 sources
- drugamoxicillin12 co-mentions · 12 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 14 approved and 2 investigational indications.
targets
Potassium-transporting ATPase
all catalysts(3)
approval · 3
Nov 1, 2023
approval
$PHAT8.6000-7.73%
VOQUEZNA (VONOPRAZAN FUMARATE) — FDA approval
vonoprazan fumarate
→
Jul 17, 2024
approval
$PHAT8.6000-7.73%
VOQUEZNA (VONOPRAZAN FUMARATE) — FDA approval
vonoprazan fumarate
→
Nov 6, 2025
approval
$PHAT8.6000-7.73%
VOQUEZNA (VONOPRAZAN FUMARATE) — FDA approval
vonoprazan fumarate
→
Trials studying vonoprazan fumarate
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 1, 2026
72 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Aug 11, 2030formulationUS 91864114.0y
- Aug 11, 2030formulationUS 91864114.0y
- Apr 10, 2030compositionUS 79774883.6y
- Apr 10, 2030compositionUS 79774883.6y
FDA exclusivities (7)
- May 3, 2032GAINGAIN Antibiotic (5y)
- May 3, 2032GAINGAIN Antibiotic (5y)
- Jul 17, 2027I-948Indication (3y)330d
- May 3, 2027NCENew Chemical Entity (5y)255d
- May 3, 2027NCENew Chemical Entity (5y)255d
- Nov 1, 2026NPNP72d
- Nov 1, 2026NPNP72d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that